Orion Q2 2026 slides: Nubeqa drives 69% profit surge

Orion Q2 2026 slides: Nubeqa drives 69% profit surge, stock hits high

U.S. futures slide with AI worries in focus; Netflix disappoints Introduction & Market Context Orion Corporation (HEL:ORNBV) released its half-year financial report on July 17, 2026, revealing accelerating growth and significantly improved profitability driven primarily by its prostate cancer treatment Nubeqa®. The Finnish pharmaceutical company reported second-quarter operating profit growth of 68.8% and raised its full-year guidance, prompting investors to push shares up 10.86% to $75.75, near the 52-week high of $75.85. The presentation highlighted net sales growth of 25.2% in the second quarter and 21.8% for the first half, with operating margins expanding to 33.9% in Q2 from 25.1% a year earlier.

The company beat analyst expectations, reporting earnings per share of EUR 1.00 versus the forecast of EUR 0.9552, while revenue came in at EUR 522 million against expectations of EUR 505.29 million. Quarterly Performance Highlights As shown in the following chart of Q2 2026 financial performance, Orion demonstrated strong year-over-year improvements across all key metrics. Net sales reached EUR 521.6 million in the second quarter, up from EUR 416.5 million in the prior-year period.

Operating profit surged to EUR 176.6 million from EUR 104.6 million, while the operating margin expanded 880 basis points to 33.9%. Earnings per share climbed 69.7% to EUR 1.00. For the first half of 2026, the company reported similarly robust results, with net sales of EUR 939.3 million and operating profit of EUR 291.3 million, representing increases of 21.8% and 59.6%, respectively.

The company attributed the strong performance to "growth accelerated and profitability improved," with particular strength in Nubeqa® royalties and product sales, along with what it described as a "great quarter for Branded Products." Segment Analysis The following waterfall chart illustrates the contribution of each business segment to overall net sales growth in the second quarter. Innovative Medicines dominated growth, contributing EUR 95.0 million of the EUR 105.1 million total increase.

Branded Products added EUR 10.3 million, while Fermion contributed EUR 3.6 million. Generics and Consumer Health declined slightly by EUR 1.1 million, and Animal Health decreased EUR 2.9 million. The operating profit bridge reveals that royalties were the single largest driver of profitability improvement, adding EUR 76.6 million to operating profit in the quarter.

Changes in sales volume contributed EUR 17.3 million, while fixed costs increased by EUR 15.2 million, reflecting planned expansion investments. The company noted that fixed costs of EUR 50 million in Q2 were in line with strategic plans to expand clinical, regulatory, and commercial capabilities, particularly in the United States. Nubeqa® Performance and Innovative Medicines Nubeqa®, Orion’s darolutamide-based prostate cancer treatment developed in partnership with Bayer, continued its trajectory as the company’s primary growth engine.

The following chart shows the dramatic acceleration in both royalties and product sales. Innovative Medicines net sales reached EUR 241.6 million in Q2, representing 64.8% growth from EUR 146.7 million in the prior-year quarter. For the first half, the segment generated EUR 392.0 million, up 60.3% year-over-year.

Nubeqa® accounted for EUR 236.8 million of Q2 segment sales and EUR 381.8 million of H1 sales. According to the earnings call, Nubeqa® reached the maximum royalty tier during the second quarter. Chief Financial Officer René Lindell noted that once this level is reached, future quarters will be driven more by market sales growth than by further tier progression.

Management indicated that royalty income was approximately EUR 77 million in Q2, with the remainder coming from product sales to Bayer. The company cautioned that quarterly deliveries may fluctuate due to manufacturing campaign timing and a planned maintenance break in Q3, with Q4 expected to return to full manufacturing capacity. Branded Products and Other Segments Branded Products delivered strong performance in the quarter, with net sales growing 12.8% to EUR 90.7 million.

The following breakdown shows performance by therapy area. Women’s Health showed "robust growth momentum," driven by the Divina® product range, which grew 47.6% in the first half to EUR 22.2 million. The company noted that some growth may have resulted from competitor stock-outs in Nordic markets, though underlying demand remained strong.

Respiratory products, led by Easyhaler® budesonide-formoterol, contributed significantly to growth. However, the CNS therapy area declined in Q2 due to price declines for entacapone products in certain key markets. Generics and Consumer Health remained essentially flat, with a slight 0.8% decline in Q2 net sales to EUR 133.9 million.

The company announced a license agreement with Shilpa to commercialize an intravenous nivolumab biosimilar in Europe, with an expected launch in the early 2030s. Animal Health net sales declined 7.9% in Q2 to EUR 33.9 million, which management attributed to timing of deliveries against a strong comparison period. The segment received positive news in May when Tessie® (tasipimidine oral solution) received FDA approval, with the company’s partner expected to begin commercial sales in mid-2027.

Fermion, the company’s active pharmaceutical ingredient business, grew 19.9% in Q2 to EUR 21.5 million, though management indicated this growth was mostly due to timing of deliveries and expected to level out during the second half of 2026. The company disclosed a water damage incident at one Fermion plant in Hanko during a July maintenance break but stated that based on current assessment, the incident is not expected to have a material financial impact or disrupt supply continuity. Revenue Composition and Top Products

The following chart and table provide a comprehensive view of Orion’s revenue composition and top-performing products in the first half of 2026. Innovative Medicines accounted for 42% of H1 2026 net sales, followed by Generics and Consumer Health at 28%, and Branded Products at 18%. Animal Health and Fermion contributed 7% and 4%, respectively.

Among the top 10 products, Nubeqa® dominated with EUR 381.8 million in H1 sales, representing 64.9% growth. The Easyhaler® product portfolio generated EUR 95.3 million, while entacapone products contributed EUR 44.4 million despite a 4.0% decline. The Divina® series showed exceptional growth of 47.6% to EUR 22.2 million, highlighting the strength in Women’s Health.

Pipeline and Strategic Developments Orion highlighted significant progress with ODM-212, a TEAD inhibitor targeting cancers driven by the Hippo pathway. The company’s clinical development pipeline spans multiple oncology and cardiovascular programs. The pipeline includes several darolutamide (Nubeqa®) studies in partnership with Bayer, including the ARASTEP trial for biochemical recurrence in prostate cancer and DASL-HiCaP for neo-adjuvant treatment.

Multiple opevesostat trials are being conducted with MSD for various stages of metastatic castration-resistant prostate cancer and other cancers. For ODM-212, the company reached what it described as "key milestones" during the quarter. The following timeline illustrates the program’s progress.

Phase 1 results from the TEADES study were announced at the American Society of Clinical Oncology (ASCO) meeting in May, showing the drug was "well tolerated" with "no dose-limiting toxicities" and a "clean safety profile by oncology standards." Early efficacy signals were observed in malignant pleural mesothelioma and epithelioid hemangioendothelioma (EHE). The company initiated the TEADCO Phase 1b/2 combination study in April, evaluating ODM-212 with standard treatments in mesothelioma, non-small cell lung cancer, and pancreatic cancer.

Orion received orphan drug designations for mesothelioma in both the United States and European Union during Q2 2026. Chief Executive Liisa Hurme described ODM-212 as a "potentially best-in-class" molecule with two mechanisms that could benefit patients by both inhibiting tumor growth and helping prevent resistance to current medicines. The company indicated it is not seeking a partner and plans to advance both Phase II and Phase III studies independently, with TEADES Phase 2 readout estimated for late 2027 and TEADCO Phase 1b/2 readout expected in 2029.

Sustainability and ESG Performance The company highlighted its environmental credentials, noting recognition as one of Europe’s Climate Leaders 2026 by the Financial Times. Orion’s emissions reduction roadmap shows a significant drop in combined Scope 1 and 2 emissions from approximately 44,000 tCO2e in 2016-2018 to around 14,000 tCO2e in 2023, the baseline year for its science-based climate targets.

The reduction was achieved primarily by switching to 100% carbon-free electricity at Finland sites in 2019. The company has set a science-based target of 70% reduction from the 2023 baseline by 2030. Outlook and Guidance Based on the strong first-half performance, Orion raised its full-year 2026 guidance.

The company now expects net sales of EUR 2,000-2,100 million and operating profit of EUR 650-750 million. Management indicated the lower end of the sales range was lifted by EUR 50 million due to strong first-half momentum, particularly from Nubeqa®. The company expects Nubeqa® to continue growing in the second half, though quarterly deliveries may vary due to manufacturing timing and a planned Q3 maintenance break.

Management noted that tariffs on innovative pharmaceuticals from Europe are expected to begin in October, with only a small impact anticipated in 2026 but a larger effect in 2027 if the policy remains in place. The company also highlighted ongoing expansion of its U.S. team in Boston for clinical, regulatory, and commercial work, describing the hiring as "measured" with "tens of people, not hundreds." Market Reaction and Valuation Investors responded positively to the results and raised guidance, pushing shares up 10.86% to $75.75, just $0.10 below the 52-week high of $75.85.

The stock had closed at $68.33 before the announcement, representing a gain of $7.42 per share. With a market capitalization of $12.2 billion, Orion trades at a price-to-earnings ratio of 19.95 and a PEG ratio of 0.35, suggesting the stock may be attractively priced relative to its earnings growth potential. The company offers a dividend yield of 2.64% and has maintained dividend payments for 20 consecutive years, having raised its dividend for four consecutive years.

The strong market reaction suggests investors focused on three key factors: the earnings beat, the raised guidance, and the strength of Nubeqa® royalties reaching the maximum tier. According to InvestingPro analysis, the stock is trading near its fair value, indicating the market reaction has brought shares to an appropriate level following the strong results. Full presentation: